IPSEN (OTCMKTS:IPSEY) Stock Price Down 8.3% – Here’s Why

IPSEN (OTCMKTS:IPSEY) was down 8.3% during mid-day trading on Monday . The company traded as low as $42.4080 and last traded at $42.4080. Approximately 241 shares were traded during trading, a decline of 87% from the average session volume of 1,899 shares. The stock had previously closed at $46.2280.

Analyst Upgrades and Downgrades

IPSEY has been the subject of a number of analyst reports. Barclays raised IPSEN from a “strong sell” rating to a “hold” rating in a report on Thursday. Zacks Research raised IPSEN to a “hold” rating in a research report on Friday, May 29th. Jefferies Financial Group cut IPSEN from a “hold” rating to a “moderate sell” rating in a research note on Sunday, August 2nd. Finally, HC Wainwright reissued a “buy” rating on shares of IPSEN in a research report on Tuesday, June 30th. Two research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, IPSEN presently has an average rating of “Hold”.

IPSEN Stock Down 8.3%

The stock has a 50 day moving average of $46.34 and a 200 day moving average of $46.70.

About IPSEN

Ipsen SA is a France-based biopharmaceutical company that develops and commercializes specialty medicines for serious diseases. Its primary focus areas are oncology, rare diseases and neuroscience, with research and development activities aimed at addressing conditions that often have limited treatment options.

The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and endocrine disorders, Dysport (abobotulinumtoxinA) for selected neurological and muscular conditions, and oncology treatments including Cabometyx and Onivyde.